In vitro investigation of BK-218, a new oral and parenteral cephalosporin
| Autor: | J Barabás, M Filep, A Tar, K Marossy, B Tóth-Martinez, G Barabás, T Schmidt, I Szabó, L Kiss, F. Hernádi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1990 |
| Předmět: |
Cytoplasm
medicine.drug_class Cephalosporin Microbial Sensitivity Tests Muramoylpentapeptide Carboxypeptidase medicine.disease_cause beta-Lactamases Microbiology chemistry.chemical_compound Bacterial Proteins Glucosamine Cell Wall medicine Enterococcus faecalis Escherichia coli Penicillin-Binding Proteins Pharmacology (medical) Cefoxitin Cefamandole Pharmacology biology Bacteria Pseudomonas aeruginosa biology.organism_classification Cephalosporins Infectious Diseases chemistry Hexosyltransferases Peptidyl Transferases Antibacterial activity Carrier Proteins Enterobacter cloacae medicine.drug Research Article |
| Popis: | The antibacterial activity of BK-218 was similar to that of cefamandole when it was tested against several laboratory strains. The inhibiting effect of BK-218 was greater than that of cephalexin and cefoxitin on penicillin-binding proteins of Escherichia coli HB101. This result was in close correlation with the relative inhibition of radiolabeled glucosamine incorporation (greatest with BK-218) and with the lytic effect (most intensive with BK-218). BK-218 proved to be a good inhibitor for all five of the beta-lactamases that were investigated, although two enzymes (Enterobacter cloacae P99 and Pseudomonas aeruginosa Cilote) hydrolyzed it to some extent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|